✦ LIBER ✦

Effect of simvastatin plus cetuximab/irinotecan forKRASmutant colorectal cancer and predictive value of theRASsignature for treatment response to cetuximab

✍ Scribed by Lee, Jeeyun; Hong, Yong Sang; Hong, Jung Yong; Han, Se Won; Kim, Tae Won; Kang, Hye Jin; Kim, Tae You; Kim, Kyu-pyo; Kim, Suk Hyung; Do, In-Gu; Kim, Kyoung-Mee; Sohn, Insuk; Park, Se Hoon; Park, Joon Oh; Lim, Ho Yeong; Cho, Yong Beom; Lee, Woo Yong; Yun, Seong Hyeon; Kim, Hee Cheol; Park, Young Suk; Kang, Won Ki

Book ID: 125358928
Publisher: Springer US
Year: 2014
Tongue: English
Weight: 796 KB
Volume: 32
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-014-0065-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-Effectiveness of Cetuximab, Cetuxim

Cost-Effectiveness of Cetuximab, Cetuximab Plus Irinotecan, and Panitumumab for Third and Further Lines of Treatment for KRAS Wild-Type Patients with Metastatic Colorectal Cancer

✍ Hoyle, Martin; Peters, Jaime; Crathorne, Louise; Jones-Hughes, Tracey; Cooper, C 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 378 KB

Sensitivity to previous irinotecan treat

Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer

✍ Kohei Shitara; Takashi Ura; Keitaro Matsuo; Daisuke Takahari; Tomoya Yokota; Sat 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 228 KB

Cetuximab Plus Capecitabine and Irinotec

Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104--A Randomized Trial of the German AIO CRC Study Group

✍ Moosmann, N.; von Weikersthal, L. F.; Vehling-Kaiser, U.; Stauch, M.; Hass, H. G 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 169 KB

Cetuximab Plus Irinotecan, Fluorouracil,

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

✍ Van Cutsem, E.; Kohne, C.-H.; Lang, I.; Folprecht, G.; Nowacki, M. P.; Cascinu, 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 219 KB

OP-16 Chemoembolization adopting drug el

OP-16 Chemoembolization adopting drug eluting beads preloaded with irinotecan (DEBIRI) plus cetuximab (debiritux) as second-line treatment for metastatic colorectal cancer (CRC) to the liver: Results of a clinical phase II trial

✍ Fiorentini, G.; Aliberti, C.; Coschiera, P.; Tilli, M.; Mulazzani, L.; Marqués, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 74 KB

Predictive value of epidermal growth fac

Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies

✍ Licitra, Lisa; Störkel, Stephan; Kerr, Keith M.; Van Cutsem, Eric; Pirker, Rober 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 370 KB